title: Pulmonary hypertension, right ventricular function, and clinical outcome in acute decompensated heart failure.
abstract: BACKGROUND
  Pulmonary hypertension (PH) and right ventricular (RV) dysfunction have been associated with adverse outcome in patients with chronic heart failure. However, data are lacking in the setting of acute decompensated heart failure (ADHF). We sought to determine prognostic significance of PH in patients with ADHF and its interaction with RV function.
  
  
  METHODS
  We studied 326 patients with ADHF. Pulmonary artery systolic pressure (PASP) and RV function were determined with the use of Doppler echocardiography, with PH defined as PASP >50 mm Hg. The primary end point was all-cause mortality during 1-year follow-up.
  
  
  RESULTS
  PH was present in 139 patients (42.6%) and RV dysfunction in 83 (25.5%). The majority of patients (70%) with RV dysfunction had PH. Compared with patients with normal RV function and without PH, the adjusted hazard ratio (HR) for mortality was 2.41 (95% confidence interval [CI] 1.44-4.03; P = .001) in patients with both RV dysfunction and PH. Patients with normal RV function and PH had an intermediate risk (adjusted HR 1.78, 95% CI 1.11-2.86; P = .016). Notably, patients with RV dysfunction without PH were not at increased risk for 1-year mortality (HR 1.04, 95% CI 0.43-2.41; P = .94). PH and RV function data resulted in a net reclassification improvement of 22.25% (95% CI 7.2%-37.8%; P = .004).
  
  
  CONCLUSIONS
  PH and RV function provide incremental prognostic information in ADHF. The combination of PH and RV dysfunction is particularly ominous. Thus, the estimation of PASP may be warranted in the standard assessment of ADHF.
authors.affiliation: Department of Cardiology, Rambam Medical Center; and the Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: daronson@tx.technion.ac.il.
authors.forename: Doron
authors.initials: D
authors.lastname: Aronson
authors.forename: Wisam
authors.initials: W
authors.lastname: Darawsha
authors.forename: Aula
authors.initials: A
authors.lastname: Atamna
authors.forename: Marielle
authors.initials: M
authors.lastname: Kaplan
authors.forename: Badira F
authors.initials: BF
authors.lastname: Makhoul
authors.forename: Diab
authors.initials: D
authors.lastname: Mutlak
authors.forename: Jonathan
authors.initials: J
authors.lastname: Lessick
authors.forename: Shemy
authors.initials: S
authors.lastname: Carasso
authors.forename: Shimon
authors.initials: S
authors.lastname: Reisner
authors.forename: Yoram
authors.initials: Y
authors.lastname: Agmon
authors.forename: Robert
authors.initials: R
authors.lastname: Dragu
authors.forename: Zaher S
authors.initials: ZS
authors.lastname: Azzam
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D016896:Treatment Outcome; D018497:Ventricular Dysfunction, Right / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology*; D016278:Ventricular Function, Right / Q000502:physiology
keywords: Acute heart failure; prognosis; pulmonary hypertension; right ventricle